Need a quote from a Motley Fool analyst? Over the past decade, Recursion Pharmaceuticals, Inc. has built something truly special: a differentiated platform pioneering the integration of large-scale ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

American Airlines quietly ended the ability for customers traveling on basic economy tickets to earn miles and status. Basic economy tickets are airlines' most restrictive and already do not allow for ...

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

AI-leveraged drug development has become an $18 billion industry, but companies in the sector are experiencing some hardships. Beyond efforts to convenience investors their drugs are safe and ...

The idea of a universal basic income—a taxpayer-funded minimum monthly payment meant to reduce poverty and improve opportunity—is alluring. That’s especially true for low-income mothers of newborns.

In this week’s edition of InnovationRx, we look at a new biotech fund spearheaded by Recursion, a shift in bird flu strategy from the Trump Administration, a new vaccine approval from the FDA, ...

Despite near-significant Phase 2 data, Recursion's lead drug REC-994 for CCM remains unconvincing as a validation of their AI platform, being a repurposed compound. Pipeline expansion in oncology ...